Cannabidiol (CBD) and Its Neuroprotective Effects in Animal Models of Multiple Sclerosis and Other Neurodegenerative Diseases
CBD demonstrates anti-inflammatory, antioxidant, mitochondria-protective, and neuroprotective properties in preclinical models related to multiple sclerosis and other neurodegenerative diseases. Clinical evidence, however, primarily addresses symptoms like agitation and sleep disturbances without proving disease modification.
- Most relevant to
- Neurologist, Pharmacologist
Why it matters
These findings illustrate potential pathways through which CBD might impact neurodegenerative diseases, emphasizing its therapeutic prospects and limitations in human applications yet to be fully understood.
What this does not prove
The clinical evidence remains preliminary and does not show proven disease modification. Key barriers include inconsistent bioavailability and insufficient understanding of exposure-response relationships.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- All
- Publication date
- 2026-09-23
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Neuroprotection, Neuroinflammation, Other
Original sources
Supporting passages (8)
study phaseKey barriers to development include low and variable oral bioavailability, incomplete brain exposure data, uncertain active metabolite contributions, limited target-engagement biomarkers, and insufficient exposure-response definition.
study designPreclinical studies across models of Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis consistently support CBD's anti-inflammatory, antioxidant, mitochondria-protective, and neuroprotective pharmacology.
research categoriesMajor components include cannabinoid receptors, transient receptor potential channels, peroxisome proliferator-activated receptor-γ, adenosine and serotonin signaling systems, voltage-gated calcium channels, and redox-regulatory pathways.
relevant ms typesPreclinical studies across models of Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis consistently support CBD's anti-inflammatory, antioxidant, mitochondria-protective, and neuroprotective pharmacology.
interventionCBD is a lipophilic terpenophenolic chemotype whose phenolic redox chemistry, membrane partitioning, cytochrome P450-mediated metabolism, and formulation-dependent exposure are central to its biological activity and translational limitations.
findingsClinical evidence remains preliminary and is mainly symptomatic, with signals in agitation, sleep disturbance, spasticity, quality of life, and neuropsychiatric symptoms rather than proven disease modification.
limitationsThese mechanisms converge on neuroinflammation, excitotoxicity, mitochondrial dysfunction, impaired proteostasis, and synaptic injury.
publication datePublication date: 2026-09-23
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.